BRCA1 and breast cancer: This implied that the increase in the ruthenium sensitivity in BRCA1 defective breast cancer cells might be related to a dysfunctional BRCA1 that is unable to repair DNA damage produced by ruthenium treatment, and ultimately led to breast cancer cell death[51].